Top

Category: Editorial


Editorial

Why Biopharma Industry Relies on New Science

August 30, 2021

Via: Natalie Dunn

The ongoing COVID-19 pandemic has sparked an unprecedented crisis for governments, healthcare providers, and industries across the world. Biopharmaceutical companies were especially affected, as they were left struggling to develop solutions that will ultimately help diagnose and treat those suffering […]


Editorial

Using Biopharma Breakthroughs to Fight the Delta Variant

July 30, 2021

Via: Natalie Dunn

The Delta variant of the coronavirus has become the dominant strain around the world, bringing with it an increase in deaths in the US and many other countries. While the victims are almost exclusively unvaccinated, the new surge seems to […]


Editorial

Biopharmaceuticals: A Look Into the Near Future

June 30, 2021

Via: David Dickson

In 1982, the U.S. approved human insulin—the first ever recombinant biopharmaceutical drug. Since then, biopharma development has proceeded at an exponential pace, with new innovations redefining, over and over again, the possibilities of medicine.  Going forward, biopharma will demand more […]


Editorial

5 Facts About to Change the Post-pandemic World

May 28, 2021

Via: Natalie Dunn

With COVID-19 vaccines becoming more widely available around the world, and countries everywhere easing restrictions, a return to normal is now on everyone’s mind. While many activities are still recovering and regulations remain an important part of our daily lives, […]


Editorial

What are the challenges and opportunities of biopharma?

April 30, 2021

Via: Rachel Oldford

Biopharmaceuticals are among the most complex and elegant realizations of modern science. But this complexity also comes at great cost. More exactly, biotech-manufacturing facilities need between $200 and $500 million to be built and this process could last up to […]